REGULATIONS
New health laws ‘may hit Adcock’
Share price has gone up by 22% since the start of 2017, but there was a drop of 1.5% last week, breaking two consecutive weeks of gains
Adcock Ingram’s share price has extended its growth streak outperforming the market in 2017. But an analyst has warned that the latest health regulations could put a damper on the firm. The JSE listed pharmaceutical company manufactures and markets healthcare products to both the private and public sectors. On Tuesday, the share was up 0.63%, to R59.12 from a previous close of R58.75. The share price has increased since the company announced its first cash surplus since 2011 in February. The firm raised more than R300m after selling its Indian sales and marketing business and a majority stake in the Ghanaian enterprise. Gryphon Asset Management portfolio manager Casparus Treurnicht said since the lows of January 2016, Adcock outperformed the market by 44% when it rose from R39 to current levels of R59. "Also, compared with Aspen, the share performed even better for an outperformance of 110% since the beginning of 2015." Rival Aspen was up 1.89% at R290.50 at the close of the JSE on ...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.